Nemes Rush Group’s Emergent Biosolutions EBS Stock Holding History

Nemes Rush Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-42	Closed	-$106	–	749
2024 Q3	$106	Hold	42	–	–	﹤0.01%	597
2024 Q2	$286	Hold	42	–	–	﹤0.01%	586
2024 Q1	$107	Hold	42	–	–	﹤0.01%	656
2023 Q4	$101	Hold	42	–	–	﹤0.01%	649
2023 Q3	$143	Hold	42	–	–	﹤0.01%	634
2023 Q2	$309	Buy	+42	New	+$389	﹤0.01%	658

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Nemes Rush Group's EBS Position: Q4 2024 in Review

Nemes Rush Group sold out of Emergent Biosolutions (EBS) in Q4 2024, closing a stake of 42 shares — an estimated $106 sold.

Nemes Rush Group first reported a position in EBS in Q2 2023 and held it in 6 quarters. The position peaked at $309 in Q2 2023. 156 funds tracked by Wall St. Rank hold EBS as of Q4 2024.

Nemes Rush Group reported no remaining Emergent Biosolutions position as of Q4 2024 after selling out during the quarter.
Nemes Rush Group sold 42 Emergent Biosolutions shares in Q4 2024, an estimated $106.
Nemes Rush Group first reported a position in Emergent Biosolutions in Q2 2023 and held it in 6 quarters.
Nemes Rush Group's Emergent Biosolutions position peaked at $309 in Q2 2023.
156 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2024.

Based on Nemes Rush Group's 13F filing for Q4 2024, filed 12 Feb 2025.